Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JUH2 | ISIN: PLSELVT00013 | Ticker-Symbol: 9Y4
Frankfurt
28.03.24
08:03 Uhr
12,540 Euro
-0,160
-1,26 %
Branche
Biotechnologie
Aktienmarkt
OSTEUROPA
1-Jahres-Chart
RYVU THERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
RYVU THERAPEUTICS SA 5-Tage-Chart

Aktuelle News zur RYVU THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.03.Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update94Total operating revenues for the full year 2023 were $16.3M , compared to $15.8M for the same period in 2022. As of March 7, 2024, Ryvu's cash position was $57.2M, excluding the first tranche of €8M...
► Artikel lesen
13.03.Ryvu Therapeutics posts PLN 24.3 mln in EBITDA loss, PLN 26.9 mln in EBIT loss in Q4 20231
06.03.Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank198Ryvu has met the conditions for receiving EUR 8 million in Tranche A of venture debt from the European Investment Bank (EIB) due to the progress within the RVU120 program among other factors. ...
► Artikel lesen
06.03.Ryvu Therapeutics meets conditions for disbursement of first tranche of EIB financing1
14.02.Ryvu Therapeutics: Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS72KRAKOW, Poland, Feb. 14, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging...
► Artikel lesen
31.01.Ryvu Therapeutics: Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML121KRAKOW, Poland, Jan. 31, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging...
► Artikel lesen
11.12.23Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting189Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy, including...
► Artikel lesen
07.12.23Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 20231
29.11.23Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update860The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022.Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of...
► Artikel lesen
23.10.23Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120260KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging...
► Artikel lesen
04.10.23Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics3
13.09.23Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update402The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA)...
► Artikel lesen
16.05.23Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update460Updated Clinical Data from the Ongoing Phase Ib Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS and Preclinical Data from the Combination Study of RVU120 and Ruxolitinib in Myeloproliferative...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1